Logo image of BBLG

BONE BIOLOGICS CORP (BBLG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BBLG - US0980706008 - Common Stock

1.83 USD
-0.03 (-1.45%)
Last: 12/19/2025, 8:00:01 PM
1.8299 USD
0 (-0.01%)
After Hours: 12/19/2025, 8:00:01 PM
Fundamental Rating

3

BBLG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BBLG as it has an excellent financial health rating, but there are worries on the profitability. BBLG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BBLG had negative earnings in the past year.
In the past year BBLG has reported a negative cash flow from operations.
BBLG had negative earnings in each of the past 5 years.
BBLG had a negative operating cash flow in each of the past 5 years.
BBLG Yearly Net Income VS EBIT VS OCF VS FCFBBLG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -62.13%, BBLG is in line with its industry, outperforming 40.98% of the companies in the same industry.
BBLG has a Return On Equity (-65.59%) which is in line with its industry peers.
Industry RankSector Rank
ROA -62.13%
ROE -65.59%
ROIC N/A
ROA(3y)-148.84%
ROA(5y)N/A
ROE(3y)-181.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBLG Yearly ROA, ROE, ROICBBLG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K -10K

1.3 Margins

BBLG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBLG Yearly Profit, Operating, Gross MarginsBBLG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, BBLG has more shares outstanding
The number of shares outstanding for BBLG has been increased compared to 5 years ago.
There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BBLG Yearly Shares OutstandingBBLG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
BBLG Yearly Total Debt VS Total AssetsBBLG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -14.34, we must say that BBLG is in the distress zone and has some risk of bankruptcy.
BBLG's Altman-Z score of -14.34 is on the low side compared to the rest of the industry. BBLG is outperformed by 79.51% of its industry peers.
BBLG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.34
ROIC/WACCN/A
WACCN/A
BBLG Yearly LT Debt VS Equity VS FCFBBLG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 19.00 indicates that BBLG has no problem at all paying its short term obligations.
BBLG has a better Current ratio (19.00) than 95.86% of its industry peers.
A Quick Ratio of 19.00 indicates that BBLG has no problem at all paying its short term obligations.
The Quick ratio of BBLG (19.00) is better than 95.86% of its industry peers.
Industry RankSector Rank
Current Ratio 19
Quick Ratio 19
BBLG Yearly Current Assets VS Current LiabilitesBBLG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.15% over the past year.
EPS 1Y (TTM)82.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BBLG will show a very strong growth in Earnings Per Share. The EPS will grow by 39.76% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.92%
EPS Next 2Y39.76%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BBLG Yearly EPS VS EstimatesBBLG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BBLG. In the last year negative earnings were reported.
Also next year BBLG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBLG Price Earnings VS Forward Price EarningsBBLG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBLG Per share dataBBLG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

BBLG's earnings are expected to grow with 39.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.76%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BBLG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BONE BIOLOGICS CORP

NASDAQ:BBLG (12/19/2025, 8:00:01 PM)

After market: 1.8299 0 (-0.01%)

1.83

-0.03 (-1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners0.74%
Inst Owner Change2819.34%
Ins Owners0.04%
Ins Owner Change0%
Market Cap3.29M
Revenue(TTM)N/A
Net Income(TTM)-3.95M
Analysts82.86
Price Target22.7 (1140.44%)
Short Float %2.49%
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-27.15%
Min EPS beat(2)-124.81%
Max EPS beat(2)70.51%
EPS beat(4)3
Avg EPS beat(4)-3.07%
Min EPS beat(4)-124.81%
Max EPS beat(4)70.51%
EPS beat(8)6
Avg EPS beat(8)-13.37%
EPS beat(12)9
Avg EPS beat(12)-13.21%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.11%
PT rev (3m)-1.11%
EPS NQ rev (1m)70.18%
EPS NQ rev (3m)70.18%
EPS NY rev (1m)41.29%
EPS NY rev (3m)41.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-7.3
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS0
BVpS3.34
TBVpS3.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.13%
ROE -65.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-148.84%
ROA(5y)N/A
ROE(3y)-181.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19
Quick Ratio 19
Altman-Z -14.34
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.4%
EPS Next Y91.92%
EPS Next 2Y39.76%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.91%
OCF growth 3YN/A
OCF growth 5YN/A

BONE BIOLOGICS CORP / BBLG FAQ

Can you provide the ChartMill fundamental rating for BONE BIOLOGICS CORP?

ChartMill assigns a fundamental rating of 3 / 10 to BBLG.


What is the valuation status of BONE BIOLOGICS CORP (BBLG) stock?

ChartMill assigns a valuation rating of 1 / 10 to BONE BIOLOGICS CORP (BBLG). This can be considered as Overvalued.


What is the profitability of BBLG stock?

BONE BIOLOGICS CORP (BBLG) has a profitability rating of 1 / 10.


Can you provide the financial health for BBLG stock?

The financial health rating of BONE BIOLOGICS CORP (BBLG) is 7 / 10.